Aspirin "resistance" and its impact on cardiovascular morbidity and mortality: It is real, clinically relevant and should be measured

Heart

Volumn 95, Issue 15, 2009, Pages 1223-1224

  Brister, Stephanie J ^a   Buchanan, Michael R ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

BLEEDING TIME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG SAFETY; HUMAN; LONG TERM CARE; MEASUREMENT; MORBIDITY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTE FUNCTION;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 67650759561     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.157321     Document Type: Short Survey

References (12)

1. Snoep JD, Hovens MMC, Eikenboom JCJ, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9.
2. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8.
3. Cresente M, Di Castalnuovo A, Iacoviello L, et al. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a metaanalysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129-31.
4. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-3.
5. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Aterioscler Throm Vasc Biol 2004;24:1980-7.
6. Andersen K, Hurlen M, Arnesen H, et al. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42.
7. Hegason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
8. Macchi L, Christianes L, Brabant S, et al. Resistance to aspirin is associated with platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9.
9. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-6.
10. Heindl B, Becker BF. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates post ischemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 2001;363:233-240
11. Schwartz L, Brister SJ, Bourassa MG, et al. On behalf of the BRAT Investigators. Interobserver reproducibilty and biological variability of the Surgicutt II bleeding time. J Thromb Thrombolysis 1998;6:155-8.
12. Frelinger AL III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113:2888-96.